CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

Liwen Ren,Yihui Yang,Wan Li,Xiangjin Zheng,Jinyi Liu,Sha Li,Hong Yang,Yizhi Zhang,Binbin Ge,Sen Zhang,Weiqi Fu,Dexin Dong,Guanhua Du,Jinhua Wang
DOI: https://doi.org/10.1186/s12967-022-03641-y
IF: 8.44
2022-10-03
Journal of Translational Medicine
Abstract:Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized therapeutic drug, came out in 1970 and is still the only first-line treatment for ACC in spite of serious adverse reaction and a high recurrence rate.
medicine, research & experimental
What problem does this paper attempt to address?